CSPIA
TCRT icon

Cary Street Partners Investment Advisory’s Alaunos Therapeutics TCRT Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3
Closed -$64 – 1679
2023
Q3 		$64 Hold
3
– – ﹤0.01% 1856
2023
Q2 		$248 Hold
3
– – ﹤0.01% 1710
2023
Q1 		$306 Hold
3
– – ﹤0.01% 1630
2022
Q4 		$315 Buy
+3
New +$435 ﹤0.01% 1640

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCA
Magnolia Capital Advisors Jackson, Mississippi $509M AUM 18.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Cary Street Partners Investment Advisory's TCRT Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Alaunos Therapeutics (TCRT) in Q4 2023, closing a stake of 3 shares — an estimated $64 sold.

Cary Street Partners Investment Advisory first reported a position in TCRT in Q4 2022 and held it in 4 quarters. The position peaked at $315 in Q4 2022. 82 funds tracked by Wall St. Rank hold TCRT as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Alaunos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 3 Alaunos Therapeutics shares in Q4 2023, an estimated $64.
  • Cary Street Partners Investment Advisory first reported a position in Alaunos Therapeutics in Q4 2022 and held it in 4 quarters.
  • Cary Street Partners Investment Advisory's Alaunos Therapeutics position peaked at $315 in Q4 2022.
  • 82 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.